Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension Study of Verekitug (UPB-101) in Adults with Severe Asthma Completing VALIANT
jRCT2031250399Active, not recruiting
- Sponsor
- Upstream Bio
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Randomised, double-blind trial of vereckitug in severe asthma (4 arms), sponsored by Upstream Bio. Primary endpoint: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs). Started Oct 2025; status: active, not recruiting.
02
Drugs
vereckitug
03
Conditions
severe asthma
Beyond the preview
Go deeper on jRCT2031250399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250399.